AJR ARRS: Your Link to CME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cronin, C. G.
Right arrow Articles by Bruzzi, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cronin, C. G.
Right arrow Articles by Bruzzi, J. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.09.2637
AJR 2010; 194:W91-W103
© American Roentgen Ray Society

Review

Clinical Utility of PET/CT in Lymphoma

Carmel G. Cronin1, Ronan Swords2, Mylene T. Truong3, Chitra Viswanathan3, Eric Rohren3, Francis J. Giles2, Michael O'Dwyer4 and John F. Bruzzi1

1 Department of Radiology, University College Hospital Galway, Galway University Hospitals, Newcastle Rd., Galway, Ireland.
2 Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX.
3 Department of Diagnostic Imaging, M. D. Anderson Cancer Center, Houston, TX
4 Department of Hematology, University College Hospital Galway, Galway University Hospitals, Galway, Ireland.

OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options.

CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.

Keywords: lymphoma • PET/CT


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by the American Roentgen Ray Society.